Navigation Links
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Date:6/7/2008

m an average baseline A1C of 7.9 and 7.8 percent, respectively. In the 5 mcg arm, 86 percent of study participants completed the study and in the 10 mcg arm, 87 percent completed the study. Sixty percent of the 5 mcg evaluable study participants and 61 percent of the 10 mcg evaluable study participants achieved or maintained an A1C of less than or equal to 7 percent at study end, a common target for good glucose control.

"Healthcare professionals and their patients with type 2 diabetes need a variety of treatment options to successfully manage the disease," said Jim Malone, M.D., Global Medical Director, Eli Lilly and Company. "These data are robust and show the important glucose lowering properties of BYETTA taken as monotherapy. If approved, this indication would give physicians the option to prescribe exenatide as a stand-alone treatment, which may allow for increased patient access to BYETTA."

This study was conducted following receipt of an approvable letter for a monotherapy indication from the FDA in 2005. In addition to the clinical studies included in the 2005 submission package, data from this study address requests by the FDA as a result of that approvable letter.

Treatment with exenatide also resulted in a statistically significant lowering of fasting glucose concentrations for EXE 5 mcg (-17.5+/-4 mg/dL) and EXE 10 mcg (-18.7+/-4 mg/dL) at endpoint compared with placebo (-5.2+/-4 mg/dL). A statistically significant weight loss was also noted of -6.1 pounds (EXE 5 mcg) and -6.8 pounds (EXE 10 mcg) compared with -3.2 pounds for placebo. In an oral glucose tolerance test conducted in a subset of patients (N=104), two hour serum glucose excursion decreased for EXE 5 mcg (-18.4+/-14 mg/dL) and EXE 10 mcg (-55.1+/-13 mg/dL), while this measure increased (+4.5+/-14 mg/dL) in patients treated with placebo.

In addition, fasting serum lipid profiles, including total cholesterol and high- and low-density lipoprotein, remained unchanged
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
4. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
5. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
6. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
9. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Based On Naturally Resected tRNA Synthetases , ... subsidiary of aTyr Pharma in Hong Kong, today announced ... naturally occurring, resected human tRNA synthetases. Although tRNA ... machinery found in all organisms, human synthetases have naturally ...
... RICHMOND, Calif., June 29 Sangamo BioSciences, Inc. (Nasdaq: ... research milestone has been achieved in its Research and ... the Roche Group, for the generation of cell lines ... Sangamo,s proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. ...
Cached Medicine Technology:Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3
(Date:7/10/2014)... of Health and Human Services (HHS) has announced a ... Seidman Cancer Center totaling $4.7 million to support a ... with complex cancer. , Titled "Evidence-Conformant Oncology Care," ... UH to enhance care for adult cancer patients with ... health care utilization. , "We believe that ...
(Date:7/10/2014)... The benefits of medical imaging far outweigh the ... Right Way, with The Right Radiation Dose. However, overuse ... Mayo Clinic is leading a collaborative effort to ensure ... published online in the Journal of Patient Safety ... Joint Commission, the Intersociety Accreditation Commission, and the Centers ...
(Date:7/10/2014)... (July 10, 2014) A research review identifying the ... important first step in the process of developing evidence-based ... a new report published by Neurosurgery ... Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , Based on ...
(Date:7/10/2014)... Depressed men with localized prostate cancer were more ... cancer, received less effective treatments and survived for ... not depressed, a UCLA study has found. , ... several factors such as bias against the mentally ... depressed man,s lack of investment in his general ...
(Date:7/10/2014)... prove useful in treating small cell lung cancer - the ... Cancer Research UK Manchester Institute, based at The University of ... up with experts at AstraZeneca, as part of a collaboration ... AZD3965 - on small cell lung cancer cells. , The ... also helps identify which patients are most likely to respond ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:New drug active against most aggressive type of lung cancer cells 2
... privacy in the healthcare sector is an issue of ... address the various issues raised by healthcare consumers regarding ... compliance. Writing in the International Journal of ... Johnson of Dartmouth College, Hanover, New Hampshire, USA, explain ...
... of Southern California (USC) has announced a $24 million charitable ... multi-million dollar gift will support cancer research directed by renowned ... School of Medicine of USC and director of the USC ... Cancer Center. The donation to the Keck ...
... HealthDay Reporter , THURSDAY, July 15 (HealthDay News) -- ... percent watch more than the recommended two hours of television ... rest of the country," said study co-author Dr. John Oh, ... Disease Control and Prevention, working with Oregon Public Health. ...
... Cancer Research Institute (CRI) is conducting a clinical trial that ... Lymphoma, which affects the white blood cells ... or T-cell. About 85% of lymphomas are of B-cell origin, ... chronic, but they do not respond well to chemotherapy. ...
... used to treat cancer may someday help clean up environmental ... powder hidden underneath clothing. The novel radiation mechanism developed ... team of scientists in Japan also could help doctors more ... of treatments on healthy parts of the body. The ...
... DURHAM, N.C. -- A team of Duke University researchers ... the spread of malaria while protecting human and environmental ... mosquito-borne disease occurs will be supported by a $2.2 ... Health. "We,ll be performing experiments in 24 villages ...
Cached Medicine News:Health News:Insecurities plague electronic health care 2Health News:Keck School of Medicine of USC receives $24 million gift from Sumner M. Redstone 2Health News:Keck School of Medicine of USC receives $24 million gift from Sumner M. Redstone 3Health News:Too Many Tots Watching Too Much TV: Study 2Health News:Too Many Tots Watching Too Much TV: Study 3Health News:Duke and African partners to study sustainable malaria control 2
Instrument Cover for Vibratome....
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
Medicine Products: